The global medical devices industry experienced a 13% drop in new job postings related to artificial intelligence in Q3 2022 compared with the previous quarter, according to GlobalData’s whitepaper on Artificial Intelligence in Medical Devices – Hiring Activity in Q3 2022. This compares to a 39% increase versus Q3 2021.
Notably, Software and Web Developers, Programmers, and Testers jobs accounted for a 16% share of the global medical devices industry’s artificial intelligence-related total new job postings in Q3 2022, down 11% over the prior quarter.
Software and Web Developers, Programmers, and Testers, with a share of 16%, emerged as the top artificial intelligence-related job roles within the medical devices industry in Q3 2022, with new job postings drop by 11% quarter-on-quarter. General and Operations Managers came in second with a share of 5% in Q3 2022, with new job postings rise by 4% over the previous quarter.
The other prominent artificial intelligence roles include Maintenance and Repair Workers, General with a 4% share in Q3 2022, Computer and Information Systems Managers with a 3% share of new job postings.
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q3 2022 were Medtronic, Align Technology, Thermo Fisher Scientific and ResMed. Together they accounted for a combined share of 0.36% of all artificial intelligence-related active jobs in the medical devices industry.
Medtronic posted 409 jobs in Q3 2022 and registered a rise of % over the previous quarter, followed by Align Technology with 401 jobs and a 60% drop. Thermo Fisher Scientific with 226 jobs and ResMed with 208 jobs, recorded a 28% growth and a 36% increase, respectively, while Danaher recorded a 183% increase with 147 job postings during Q3 2022.
The largest share of artificial intelligence-related new job postings in the medical devices industry in Q3 2022 was in the US with 65% followed by India (8%) and Italy (4%). The share represented by the US was two percentage points lower than the 67% share it accounted for in Q2 2022.